Click here to close Hello! We notice that you are using Internet Explorer, which is not supported by Echinobase and may cause the site to display incorrectly. We suggest using a current version of Chrome, FireFox, or Safari.
Echinobase
ECB-ART-48566
Braz J Med Biol Res 2020 Feb 14;533:e8876. doi: 10.1590/1414-431X20198876.
Show Gene links Show Anatomy links

p19Arf sensitizes B16 melanoma cells to interferon-β delivered via mesenchymal stem cells in vitro.

Da-Costa RC , Vieira IL , Hunger A , Tamura RE , Strauss BE .


Abstract
The immune stimulatory and anti-neoplastic functions of type I interferon have long been applied for the treatment of melanoma. However, the systemic application of high levels of this recombinant protein is often met with toxicity. An approach that provides localized, yet transient, production of type I interferon may overcome this limitation. We propose that the use of mesenchymal stem cells (MSCs) as delivery vehicles for the production of interferon-β (IFNβ) may be beneficial when applied together with our cancer gene therapy approach. In our previous studies, we have shown that adenovirus-mediated gene therapy with IFNβ was especially effective in combination with p19Arf gene transfer, resulting in immunogenic cell death. Here we showed that MSCs derived from mouse adipose tissue were susceptible to transduction with adenovirus, expressed the transgene reliably, and yet were not especially sensitive to IFNβ production. MSCs used to produce IFNβ inhibited B16 mouse melanoma cells in a co-culture assay. Moreover, the presence of p19Arf in the B16 cells sensitizes them to the IFNβ produced by the MSCs. These data represent a critical demonstration of the use of MSCs as carriers of adenovirus encoding IFNβ and applied as an anti-cancer strategy in combination with p19Arf gene therapy.

PubMed ID: 32077463
PMC ID: PMC7025448
Article link: Braz J Med Biol Res


Genes referenced: LOC100892350 LOC115919910


Article Images: [+] show captions
References [+] :
Belardelli, Interferon-alpha in tumor immunity and immunotherapy. 2002, Pubmed